# Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

> **NCT03421639** · PHASE4 · UNKNOWN · sponsor: **Centre for Endocrinology and Reproductive Medicine, Italy** · enrollment: 300 (estimated)

## Conditions studied

- Uterine Adenomyosis
- Recurrent Implantation Failure
- Menstrual Pain

## Interventions

- **DRUG:** GnRH analog (11.25mg Leuprolide acetate)
- **DRUG:** Aromatase inhibitor and GnRH analog
- **DRUG:** Aromatase and GnRH analog (11.25mg Leuprolide acetate)

## Key facts

- **NCT ID:** NCT03421639
- **Lead sponsor:** Centre for Endocrinology and Reproductive Medicine, Italy
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421639, "Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT03421639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*